Novel drugs against tuberculosis: A clinician's perspective

European Respiratory Journal

Volumn 45, Issue 4, 2015, Pages 1119-1131

  Olaru, Ioana Diana ^a   Von Groote Bidlingmaier, Florian ^b   Heyckendorf, Jan ^a   Yew, Wing Wai ^c   Lange, Christoph ^a,d,e,f   Chang, Kwok Chiu ^g  

^a RESEARCH CENTER BORSTEL   (Germany)

^b Karl Bremer Hospital   (South Africa)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF LÜBECK   (Germany)

^e UNIVERSITY OF NAMIBIA   (Namibia)

^f KAROLINSKA INSTITUTE   (Sweden)

^g DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOSALICYLIC ACID; ANTIVIRUS AGENT; BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; CREATININE; CYCLOSERINE; DELAMANID; EFAVIRENZ; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NEVIRAPINE; PLACEBO; POSIZOLID; PRETOMANID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RITONAVIR; STREPTOMYCIN; SUTEZOLID; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; ADAMANTANE; ETHYLENEDIAMINE DERIVATIVE; N-GERANYL-N'-(2-ADAMANTYL)ETHANE-1,2-DIAMINE; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PNU-100480; QUINOLINE DERIVATIVE;

AREA UNDER THE CURVE; ARTHRALGIA; BONE MARROW SUPPRESSION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSGLYCEMIA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; INFECTION RISK; LEUKOCYTE COUNT; LIVER INJURY; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NAUSEA; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TUBERCULOSIS; ANALOGS AND DERIVATIVES; DRUG COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FOLLOW UP; MALE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADAMANTANE; ANTITUBERCULAR AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIARYLQUINOLINES; DRUG THERAPY, COMBINATION; ETHYLENEDIAMINES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NITROIMIDAZOLES; OXAZOLES; OXAZOLIDINONES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84926506498     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00162314     Document Type: Review

References (139)

1. Yew WW, Lange C, Leung CC. Treatment of tuberculosis update 2010. Eur Respir J 2010; 37: 441-462.
2. th Edn. Geneva, World Health Organization, 2010.
3. Iseman MD, Goble M. Treatment of tuberculosis. Adv Intern Med 1988; 33: 253-266.
4. American Thoracic Society, Center for Disease Control. Treatment of tuberculosis and other mycobacterial disease. Am Rev Respir Dis 1983; 127: 790-796.
5. Mitchison DA. Treatment of tuberculosis. The Mitchell Lecture 1979. J Roy Coll Phys London 1980; 14: 91-99.
6. Fox W, Mitchison DA. Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1975; 111: 325-353.
7. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1975; 1: 119-124.
8. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet 1976; 2: 1102-1104.
9. Tripathy SP. Madras study of short-course chemotherapy in pulmonary tuberculosis. Bull Int Union Tuberc Lung Dis 1979; 54: 28-30.
10. Somner AR. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic Association (third report). Lancet 1980; 1: 1182-1183.
11. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 1990; 112: 397-406.
12. Heyckendorf J, Olaru ID, Ruhwald M, et al. Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2014; 190: 374-383.
13. World Health Organization. Management of MDR-TB: a Field Guide: a Companion Document to Guidelines for Programmatic Management of Drug-resistant Tuberculosis: Integrated Management of Adolescent and Adult Illness (IMAI). Geneva, World Health Organization, 2009.
14. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Emergency Update 2008. Geneva, World Health Organization, 2008.
15. World Health Organization. Global Tuberculosis Report 2012. Geneva, World Health Organization, 2012.
16. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42: 156-168.
17. van der Werf MJ, Kodmon C, Hollo V, et al. Drug resistance among tuberculosis cases in the European Union and European Economic Area, 2007 to 2012. Euro Surveill 2014; 19: 20733.
18. Ponce M, Ugarte-Gil C, Zamudio C, et al. Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru. Trans R Soc Trop Med Hyg 2012; 106: 508-510.
19. Matthys F, Rigouts L, Sizaire V, et al. Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS One 2009; 4: e7954.
20. Van Deun A, Maug AKJ, Salim MAH, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
21. World Health Organization. Definitions and Reporting Framework for Tuberculosis - 2013 Revision. Geneva, World Health Organization, 2013.
22. Günther G, Gomez GB, Lange C, etal. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J 2015; 45: 1081-1089.
23. Chang KC, Dheda K. Rationalizing use of fluoroquinolones and pyrazinamide in the battle against multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2013; 188: 10-11.
24. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-1481.
25. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
26. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
27. Koh WJ, Kang YR, Jeon K, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 2012; 67: 1503-1507.
28. Chang KC, Yew WW, Cheung SW, et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother 2013; 57: 3445-3449.
29. Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
30. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769-782.
31. Treatment of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J 1952; 2: 735-746.
32. Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59: 1049-1063.
33. Cohen J. Infectious disease. Approval of novel TB drug celebrated-with restraint. Science 2013; 339: 130.
34. European Medicines Agency, Press Release. European Medicines Agency Recommends Approval of a New Medicine for Multidrug-resistant Tuberculosis. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/12/news-detail-001999.jsp&mid=WC0b01ac058004d5c1 December 20, 2013. Date last accessed: August 29, 2014.
35. Johnson and Johnson, Press Release. SIRTURO® (bedaquiline) Receives Conditional Approval in the European Union for the Treatment of Multi-drug Resistant Tuberculosis. www.investor.jnj.com/releasedetail.cfm?ReleaseID=831021 March 6, 2014. Date last accessed: July 24, 2014.
36. US Food and Drug Administration. FDA News Release on Bedaquiline Approval. www.fda.gov/newsevents/newsroom/pressannouncements/ucm333695.htm December 31, 2012. Date last accessed: August 29, 2014.
37. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-227.
38. Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008; 283: 25273-25280.
39. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-2981.
40. Andries K, Villellas C, Coeck N, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014; 9: e102135.
41. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis. MMWR Recomm Rep 2013; 62: 1-12.
42. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
43. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-3276.
44. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
45. Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55: 5485-5492.
46. Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 3114-3120.
47. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
48. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32: 359-378.
49. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
50. rd Interscience Conference on Antimicrobial Agents and Chemotherapy: Abstract A1259. www.icaaconline.com/php/icaac2013abstracts/data/papers/2012/A/2012-A-1259.htm
51. European Medicines Agency. Summary of Opinion. Delamanid. www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion-Initial-authorisation/human/002552/WC500155458.pdf November 21, 2013. Date last accessed: July 24, 2014.
52. European Medicines Agency. Deltyba Product Infomation.www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002552/WC500166232.pdf Date last accessed: July 24, 2014.
53. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3: e466.
54. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
55. Singh R, Manjunatha U, Boshoff HIM. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008; 322: 1392-1395.
56. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824 novel insights from transcriptional profiling. Commun Integr Biol 2009; 215-218.
57. Somasundaram S, Anand RS, Venkatesan P, et al. Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor. BMC Microbiol 2013; 13: 218-218.
58. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-966.
59. Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 2009; 53: 3720-3725.
60. Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005; 49: 2294-2301.
61. Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005; 49: 2289-2293.
62. Feuerriegel S, Köser CU, Baú D, et al. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother 2011; 55: 5718-5722.
63. Manjunatha UH, Boshoff H, Dowd CS, et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103: 431-436.
64. Hartkoorn RC, Ryabova OB, Chiarelli LR, et al. Mechanism of action of 5-nitrothiophenes against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2944-2947.
65. Hu Y, Coates ARM Mitchison DA Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008; 12: 69-73.
66. Global Alliancefor TB. Drug Development. Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-resistant Pulmonary Tuberculosis (TB) 2013. http//clinicaltrials.gov/ct2/show/NCT01498419 Date last updated: March 12, 2013.
67. Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother 2009; 53: 3726-3733.
68. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010; 54: 3402-3407.
69. Diacon AH, Dawson R, du Bois J, et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 2012; 56: 3027-3031.
70. Effect of PA-824 and of PA-824 Plus Moxifloxacinon the QTc Interval in Healthy Volunteers. http://clinicaltrials.gov/ct2/show/NCT01674218?term=NCT01674218&rank=1 Date last updated: February 14, 2013. Date last accessed: April 8, 2014.
71. Barbachyn MR, Hutchinson DK, Brickner SJ, et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996; 39: 680-685.
72. Yip PC, Kam KM, Lam ET, et al. In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2013; 42: 96-97.
73. Wallis RS, Jakubiec W, Kumar V, et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011; 55: 567-574.
74. Wallis RS, Dawson R, Friedrich SO, et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One 2014; 9: e94462.
75. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
76. Balasubramanian V, Solapure S, Iyer H, et al. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother 2014; 58: 495-502.
77. st Interscience Conference on Antimicrobial Agents and Chemotherapy: Abstract A11735. http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2789&sKey=0b498641-f10a-4936-b80c-d274ffe4b143&cKey=2271e63a-2cdc-4956-b7b0-6f7dc642b346&mKey=0c918954-d607-46a7-8073-44f4b537a439
78. Phase 2a EBA Trial of AZD5847. http://clinicaltrials.gov/show/NCT01516203 Date last updated: April 16, 2014. Date last accessed: June 29, 2014.
79. Tahlan K, Wilson R, Kastrinsky DB, et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 1797-1809.
80. The HIV i-Base/Treatment Action Group. 2013 Pipeline Report: HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development. Benzacar A, Horn T, Morgan S, eds. London, HIV i-Base, 2013.
81. Svensson EM, Aweeka F, Park JG, et al. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother 2013; 57: 2780-2787.
82. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharm Ther 2002; 72: 1-9.
83. Dooley KE, Park JG, Swindells S, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr 2012; 59: 455-462.
84. th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Abstract MOPE172. http://pag.ias2011.org/abstracts.aspx?aid=1350.
85. Sow FB, Alvarez GR, Gross RP, et al. Role of STAT1, NF-kappaB, and C/EBPbeta in the macrophage transcriptional regulation of hepcidin by mycobacterial infection and IFN-gamma. J Leukoc Biol 2009; 86: 1247-1258.
86. Dooley KE, Kim PS, Williams SD, et al. Pharmacology Research Priorities. AIDS Res Treat 2012; 2012: 874083.
87. nd Interscience Conference on Antimicrobial Agents and Chemotherapy: Abstract A-1255. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=a96a704b-ee24-44df-8955-f1688acf7663&cKey=0be05c32-0d75-4e82-9117-0b465a0e1daf&mKey={6B114A1D-85A4-4054-A83B-04D8B9B8749F}
88. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 2054-2058.
89. Sacksteder KA, Protopopova M Barry CE 3rd, et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol 2012; 7: 823-837.
90. Spigelman M, Woosley R, Gheuens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis 2010; 14: 663-664.
91. World Health Organization. Anti-tuberculosis Drug Resistance in the World: Fourth Global Report. Geneva, World Health Organization, 2008.
92. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380: 1406-1417.
93. Chang KC, Yew WW, Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother 2011; 55: 4499-4505.
94. Pierre-Audigier C, Surcouf C, Cadet-Daniel V, et al. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16: 221-223.
95. Global Alliancefor TB. Drug Development. Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (NC-003). http://clinicaltrials.gov/ct2/show/NCT01691534?term=NCT01691534&rank=1 Date last updated: April 11, 2013.
96. Reddy VM, Einck L, Andries K, et al. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010; 54: 2840-2846.
97. Wallis RS, Jakubiec W, Mitton-Fry M, et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 2012; 7: e30479.
98. Reddy VM, Dubuisson T, Einck L, et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2012; 67: 1163-1166.
99. Tasneen R, Tyagi S, Williams K, et al. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2008; 52: 3664-3668.
100. Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007; 51: 1011-1015.
101. Mitchison DA, Chang KC. Experimental models of tuberculosis: can we trust the mouse? Am J Respir Crit Care Med 2009; 180: 201-202.
102. Diacon AH, Donald PR. The early bactericidal activity of antituberculosis drugs. Expert Rev Anti Infect Ther 2014; 12: 223-237.
103. Phillips PP, Gillespie SH, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis 2012; 205: Suppl. 2: S250-S257.
104. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
105. Deltyba: New Antibacterial for Multidrug-resistant Tuberculosis. http://www.mims.co.uk/deltyba-new-antibacterial-multidrug-resistant-tuberculosis/infections-and-infestations/article/1298056. Date last updated: June 16, 2014. Date last accessed: July 24, 2014.
106. Alsaad N, Wilffert B, van Altena R, et al. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. Eur Respir J 2014; 43: 884-897.
107. Gunther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med 2014; 14: 279-285.
108. Agrawal YP, Rennert H. Pharmacogenomics and the future of toxicology testing. Clin Lab Med 2012; 32: 509-523.
109. Orellana-Paucar AM, Afrikanova T, Thomas J, et al. Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy. PLoS One 2013; 8: e81634-
110. Lin PL, Coleman T, Carney JP, et al. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother 2013; 57: 4237-4244.
111. Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of tuberculosis: a review. Pharmacogenomics Pers Med 2012; 5: 89-98.
112. Misra A, Hickey AJ, Rossi C, et al. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 2011; 91: 71-81.
113. Miller JB, Abramson HA, Ratner B. Aerosol streptomycin treatment of advanced pulmonary tuberculosis in children. Am J Dis Child 1950; 80: 207-237.
114. Sacks LV, Pendle S, Orlovic D, et al. Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. Clin Infect Dis 2001; 32: 44-49.
115. Justo OR, Moraes AM. Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment. J Pharm Pharmacol 2005; 57: 23-30.
116. Dharmadhikari AS, Kabadi M, Gerety B, et al. single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother 2013; 57: 2613-2619.
117. Verma RK, Germishuizen WA, Motheo MP, et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother 2013; 57: 1050-1052.
118. Park JH, Jin HE, Kim DD, et al. Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int J Pharm 2013; 441: 562-569.
119. Rojanarat W, Nakpheng T, Thawithong E, et al. Levofloxacin-proliposomes: opportunities for use in lung tuberculosis. Pharmaceutics 2012; 4: 385-412.
120. Rojanarat W, Nakpheng T, Thawithong E, et al. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv 2012; 19: 334-345.
121. Garcia-Contreras L, Sung JC, Muttil P, et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother 2010; 54: 1436-1442.
122. Sung JC, Garcia-Contreras L, Verberkmoes JL, et al. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother 2009; 53: 1338-1343.
123. Efremenko YV, Arjanova OV, Prihoda ND, et al. Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patients. Immunotherapy 2012; 4: 273-282.
124. Nunn A, Phillips PP, Abubakar I. Treatment of pulmonary tuberculosis. Curr Opin Pulm Med 2013; 19: 273-279.
125. Schon T, Lerm M, Stendahl O. Shortening the "short-course" therapy: insights into host immunity may contribute to new treatment strategies for tuberculosis. J Intern Med 2013; 273: 368-382.
126. Bourinbaiar AS, Mezentseva MV, Butov DA, et al. Immune approaches in tuberculosis therapy: a brief overview. Expert Rev Anti Infect Ther 2012; 10: 381-389.
127. Gao XF, Yang ZW, Li J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int J Infect Dis 2011; 15: e594-600.
128. Uhlin M, Andersson J, Zumla A, et al. Adjunct immunotherapies for tuberculosis. J Infect Dis 2012; 205 Suppl. 2: S325-S334.
129. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004; 9: 1701-1719.
130. von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24: 675-685.
131. Yang XY, Chen QF, Li YP, et al. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One 2011; 6: e23826.
132. Efremenko YV, Butov DA, Prihoda ND, et al. Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7). Hum Vaccin Immunother 2013; 9: 1852-1856.
133. Butov DA, Efremenko YV, Prihoda ND, et al. Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7). Immunotherapy 2013; 5: 1047-1054.
134. Arjanova OV, Prihoda ND, Yurchenko LV, et al. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Immunotherapy 2011; 3: 181-191.
135. Butov DA, Efremenko YV, Prihoda ND, et al. Adjunct immune therapy of first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV. Immunotherapy 2012; 4: 687-695.
136. Ahsan MJ, Garg SK, Vashishtha B, et al. Tuberculosis vaccines: hopes and hurdles. Infect Disord Drug Targets 2013; 13;3: 318-321.
137. Pitt JM, Blankley S, McShane H, et al. Vaccination against tuberculosis: how can we better BCG? Microb Pathog 2013; 58: 2-16.
138. Horvath CN, Xing Z. Immunization strategies against pulmonary tuberculosis: considerations of T cell geography. Adv Exp Med Biol 2013; 783: 267-278.
139. Kaufmann SH, Lange C, Rao M, et al. Progress in tuberculosis vaccine development and host-directed therapies - a state of the art review. Lancet Respir Med 2014; 2: 301-320.